CliffBio
biologic

FESILTY

fibrinogen, human–chmt

Loss of exclusivityDecember 2037projected — 12-year biologic exclusivity estimate
CompanyGrifols →View the full company profile on CliffBio

Drug detail

Brand nameFESILTY
Active ingredientfibrinogen, human–chmt
Strength1G/50ML
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2025
Marketing statusRx

More from Grifols

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

FESILTY patent cliff — loss of exclusivity December 2037 | CliffBio